Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US

Maria C Schneeweiss, Sandra Leonard, Andrew Weckstein, Sebastian Schneeweiss, Jeremy A Rassen
doi: https://doi.org/10.1101/2020.07.22.20159855

Article usage

Article usage: July 2020 to December 2024

AbstractFullPdf
Jul 20207460156
Aug 2020310098
Sep 202091079
Oct 202067050
Nov 202061027
Dec 202052031
Jan 202176025
Feb 202185518
Mar 202161422
Apr 202187822
May 202186727
Jun 202158615
Jul 202146419
Aug 202141417
Sep 202168322
Oct 202161137
Nov 202144329
Dec 202147324
Jan 202257912
Feb 2022102216
Mar 202279316
Apr 20224719
May 2022471122
Jun 202239012
Jul 202227517
Aug 202267318
Sep 202253336
Oct 202239217
Nov 202239415
Dec 202223415
Jan 202331817
Feb 202324719
Mar 202319710
Apr 2023301419
May 202321322
Jun 202321619
Jul 202325313
Aug 2023201412
Sep 2023281715
Oct 202325216
Nov 202324915
Dec 2023828
Jan 202427310
Feb 202416615
Mar 2024313617
Apr 202425820
May 2024281015
Jun 202414911
Jul 202423718
Aug 202436820
Sep 2024421019
Oct 2024221014
Nov 202423515
Dec 2024425
Back to top
Posted July 24, 2020.
Download PDF
Data/Code
Email
Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US
Maria C Schneeweiss, Sandra Leonard, Andrew Weckstein, Sebastian Schneeweiss, Jeremy A Rassen
medRxiv 2020.07.22.20159855; doi: https://doi.org/10.1101/2020.07.22.20159855
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area